• / Free eNewsletters & Magazine
  • / My Account
Home>Sorrento Therapeutics Announces Three Preclinical Poster Presentations on Cynviloq™, its Novel Antibody Drug Conjugate Linker Technology and c-Met/EGFR Bispecific ADC at the 106th Annual Meeting of ...

Sorrento Therapeutics Announces Three Preclinical Poster Presentations on Cynviloq™, its Novel Antibody Drug Conjugate Linker Technology and c-Met/EGFR Bispecific ADC at the 106th Annual Meeting of ...

3party Content

Sat, 18 Apr 2015

Sorrento Therapeutics Announces Three Preclinical Poster Presentations on Cynviloqâ„¢, its Novel Antibody Drug Conjugate Linker Technology and c-Met/EGFR Bispecific ADC at the 106th Annual Meeting of the American Association for Cancer Research
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.